News

Severe anaphylaxis in children predicts biphasic reactions


 

FROM THE ANNALS OF ALLERGY, ASTHMA, AND IMMUNOLOGY

References

Children who present with a severe anaphylactic reaction are two to three times more likely to develop a second delayed, or late-phase, reaction, Dr. Waleed Alqurashi and his colleagues reported.

Their retrospective study found that of 484 children who came to the emergency department for anaphylaxis, 15% developed a biphasic reaction. Most of these (69%) were respiratory and/or cardiovascular; half required epinephrine (Ann. Allerg. Asth. Immunol. 2015 [doi.org/10.1016/j.anai.2015.05.013]).

Dr. Waleed Alqurashi Michele Sullivan/Frontline Medical News

Dr. Waleed Alqurashi

Dr. Alqurashi of the pediatric department at the University of Ottawa and his associates identified five independent predictors of a biphasic reaction: age 6-9 years (odds ratio, 3.6); a delay in presentation of more than 90 minutes after the onset of the initial reaction (OR, 2.58); wide pulse pressure at triage (OR, 2.92); requiring more than one epinephrine dose for initial reaction (OR, 2.7); and needing inhaled beta-agonists at the ED (OR, 2.39).

Children with these characteristics should stay for observation, rather than being discharged when their initial reactions are stabilized, the authors wrote.

“This period should be individualized and based primarily on the degree of severity of the initial anaphylactic reaction. Given the relatively high sensitivity of the present predictors, children with mild anaphylaxis who do not match any of these predictors could be considered for early disposition from the ED (less than 6 hours timed from the onset of the anaphylactic reaction) as long as an appropriate counseling has been provided,” the investigators said. Nonetheless, Dr. Alqurashi and his associates think large-scale prospective pediatric studies are necessary to validate these predictors.

Dr Alqurashi and his associates have no financial disclosures.

msullivan@frontlinemedcom.com

On Twitter @Alz_Gal

Recommended Reading

European cardiologists seek involvement in acute stroke
MDedge Emergency Medicine
First EDition: News for and about the practice of Emergency Medicine
MDedge Emergency Medicine
FDA approves cangrelor, an intravenous antiplatelet drug
MDedge Emergency Medicine
Idarucizumab reverses dabigatran’s anticoagulant effects
MDedge Emergency Medicine
CVD becomes second-largest cause of death in U.K.
MDedge Emergency Medicine
SVS: Four easy preop variables predict mortality in ruptured AAAs
MDedge Emergency Medicine
Pediatric PH a growing burden, national study finds
MDedge Emergency Medicine
Extended warfarin delays return of unprovoked pulmonary embolism
MDedge Emergency Medicine
High VTE recurrence risk persists for at least 3 years
MDedge Emergency Medicine
Malpractice Counsel
MDedge Emergency Medicine